Byung Sun Lee

This inventor holds 5 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignee: Hanmi Science Co., Ltd.. Active years: 2015-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Byung Sun Lee. Retrieved from https://idiyas.com/inventor/byung-sun-lee-nsu2api6

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 8)

% Patents Active = 20.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 10(Granted Patents)

Company Filing History:

5 out of 63

Hanmi Science Co., Ltd.

patents

Years Active: 2015-2018

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9867777 - Liquid formulations for long-acting G-CSF conjugate (2018-01-16),

2. 9597378 - Blood coagulation factor VII and VIIa derivatives, conjugates and complexes comprising the same, and use thereof (2017-03-21),

3. 9243237 - Method for mass production of factor VII/VIIA (2016-01-26),

4. 9186415 - Long-acting human follicle-stimulating hormone formulation using immunoglobulin fragment (2015-11-17),

5. 9061072 - Liquid formulation of long-acting human growth hormone conjugate (2015-06-23),

Title: Byung Sun Lee: Pioneering Innovations in Biopharmaceuticals

Introduction

Byung Sun Lee is a distinguished inventor based in Seoul, South Korea. With an impressive portfolio of five patents, he has made significant contributions to the field of biopharmaceuticals. His innovative work focuses on enhancing the stability and efficacy of therapeutic agents, particularly in relation to blood coagulation and growth factors.

Latest Patents

Among his latest patents, Byung Sun Lee has developed a liquid formulation for long-acting G-CSF conjugates. This formulation introduces a stabilizer composition that includes buffers and mannitol, ensuring prolonged in vivo duration and stability without the concerns associated with human serum albumin. Additionally, he has worked on blood coagulation factor VII and VIIa derivatives. His innovative approach involves linking a polymer to extend the blood half-life of these derivatives, resulting in novel conjugates and complexes that have significant implications for the treatment of hemophilia.

Career Highlights

Currently, Byung Sun Lee is associated with Hanmi Science Co., Ltd., a company known for its dedication to advancing healthcare solutions through groundbreaking research and development. His work continues to push the boundaries of existing biopharmaceutical technologies, aiming to improve patient outcomes.

Collaborations

Byung Sun Lee collaborates closely with notable colleagues including Se Chang Kwon and Sung H Hong. Their combined expertise fosters an environment of innovation, allowing them to tackle complex challenges in the biopharmaceutical industry effectively.

Conclusion

Through his innovative inventions and collaborative efforts, Byung Sun Lee exemplifies the impact of dedicated inventors in advancing medical science. His patents not only highlight his ingenuity but also contribute significantly to improving treatment options for patients around the globe. The future holds promising possibilities as he continues to innovate in the realm of biotechnology.

Profile summary based on public USPTO records.